Business Wire

X2nSat Selects LeoSat’s Laser-Enabled Data Network to Support Healthcare Communications

Share

LeoSat Enterprises, which is launching a constellation of 108 low-earth-orbit communications satellites that will provide the fastest, most secure and widest coverage data network in the world, today announced that X2nSat, the highly reliable satellite solutions provider, has selected LeoSat to support new infrastructure solutions for the ever-expanding needs of the healthcare industry.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190506005302/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

New Satellite Constellation providing the first business backbone in space for Enterprise Data. (Photo: Business Wire)

X2nSat currently offers SatBlue, a proprietary line of voice and data communications solutions tailored for the healthcare industry (including data and internet redundancy, emergency response trailers and telemedicine capabilities), which allows hospitals and medical office buildings to customize communications solutions based on their existing infrastructure, and to expand when the need for additional capabilities arises.

Whether it is through telemedicine, video conferencing or transferring medical records via broadband, hospitals and medical facilities have unique needs when it comes to communications. Network reliability and scalability are key for both service continuity and disaster recovery plans. With healthcare, a back-up communications system not only keeps the business running, it can help save lives.

With data volumes exploding, the increasing demand to move large quantities of data quickly and securely around the world is fast outpacing the infrastructure needed to carry it. LeoSat has developed a unique system architecture – a space-based MPLS network - providing Gigabits of secure connectivity with lower latencies than fiber, opening-up new possibilities for Healthcare providers looking for scalable, flexible solutions for their expanding networks.

Garrett Hill, CEO of X2nSat, said: “Technology is crucial to Healthcare. With cloud computing and Big Data becoming more and more prominent, healthcare providers are seeking a reliable, disaster-resistant backbone for effective healthcare IT management. Satellite is the missing puzzle piece for the delivery of reliable communication and data connectivity. LeoSat’s unique high throughput, low latency and highly secure data communications network will enable us to offer new data and voice connectivity solutions and work closely with healthcare providers to create effective disaster preparedness plans”.

As part of the agreement, Hill receives a designated seat on LeoSat’s Customer Technical Advisory Committee, an institution created to structure collaboration and exchange information surrounding the design, configuration, production, and launch of the LeoSat satellite constellation. Says Hill, “X2nSat’s Las Cruces, New Mexico Satellite Gateway has been designed and optimized for high-throughput satellites, and X2nSat is looking forward to collaborating with LeoSat on how best to deliver the latest generation of solutions to our enterprise customers”.

Michael Abad-Santos, SVP Americas, LeoSat said: “Satellite is often seen as a last resort for enterprise data communications. But with capabilities beyond existing satellite and fiber, including transmission speeds of 5.2 gigabits per second and latency of 20 milliseconds, LeoSat’s infrastructure is what data communications has been waiting for – a game-changing service which realizes the synergies of both worlds to re-define connectivity in terms of capacity, latency, security, efficiency and coverage. Using our unique backbone in space we can provide fast and ultra-secure point-to-point data connections to and from anywhere on earth without the need for any terrestrial landings”.

LeoSat is backed by leading satellite operators SKY Perfect JSAT and Hispasat, and the system is being developed in conjunction with Thales Alenia Space, a company with unmatched expertise in designing and manufacturing low earth orbit constellations. The high-throughput satellites (HTS) in the constellation will form a mesh network interconnected through laser links, creating an optical backbone in space which is about 1.5 times faster than terrestrial fiber backbones, thus creating a paradigm shift in the use of satellites for data connectivity – rather than a gap filler or last resort where no terrestrial alternative is available. LeoSat has already secured over 2 Billion USD in pre-launch customer agreements and was recently granted a license by the FCC to operate its network in the U.S. ENDS

NOTE TO EDITORS

To find out more about LeoSat, come along to one of the panels at Sat2019. To arrange an interview, please contact Melanie Dickie. Email: Melanie@leosat.com or call +31 6 14 22 97 62.

  • Monday 6 May, 1.30pm: An Introduction to HTS and Other Acronyms (Unveiled Theater)
  • Wednesday 8 May, 3pm: Integrating LEO Constellations Into Teleport Services (Room 147)
  • Thursday 9 May, 10:45am: Executive Round Table – LEO/MEO Systems (Room 146)

About LeoSat Enterprises

LeoSat Enterprises was established to leverage the latest developments in satellite communications technologies to develop and launch a new low-earth-orbit satellite constellation which will provide the first commercially available, business grade, extremely high-speed and secure data service worldwide. With up to 108 low-earth-orbit communications satellites in the constellation LeoSat is the first company to have all the High Throughput Satellites (HTS) in the constellation interconnected through laser links, creating an optical backbone in space which is about 1.5 times faster than terrestrial fiber backbones and without the need for any terrestrial touchpoints. This unique set of features enables LeoSat to provide instant infrastructure from anywhere to everywhere which is fast, secure and reliable.

Based in Washington DC, LeoSat is currently working with Thales Alenia Space for the low-earth-orbit constellation of Ka-band communications satellites. Once operational, the constellation will provide high-speed, low-latency and highly secure communications and bandwidth for business operations in the telecom backhaul, Energy, Maritime, Government and international business markets. Launch of the constellation is expected in 2020. www.leosat.com

About X2nSat

Founded in 1996, X2nSat provides highly reliable wireless network and communications solutions, with a commitment to making the world, business and life better with reliable communication anytime, anywhere. Working “above the cloud,” X2nSat offers the robust services of a large telecommunications company with the personalized customer care of a specialty organization, and is a leading provider of satellite technology to enterprise organizations in healthcare, utilities, and other industries. For more information, visit www.X2nSat.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Melanie Dickie
VP Marketing & Communications, LeoSat Enterprises
Tel: +31 6 14 22 97 62
Email: melanie@leosat.com

Media Contact for X2nSat:
Jena Blazer, Director of Sales and Marketing
+1.707.664.5712
jena.blazer@x2nsat.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 11:00:00 EET | Press release

Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in

Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 11:00:00 EET | Press release

Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration

Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 11:00:00 EET | Press release

Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo

Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 10:00:00 EET | Press release

Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of

Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 09:44:00 EET | Press release

Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye